Alternating two pills plus bevacizumab for advanced colon cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests a treatment plan that alternates two cancer pills and adds bevacizumab (a blood-vessel drug) for metastatic colon cancer that has come back or worsened after standard treatment. It may help shrink tumors and slow disease growth after later-line therapy options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV (metastatic) colon cancer confirmed by lab testing, and it has worsened after standard treatments like 5-FU, irinotecan, and oxaliplatin
- You have documentation that your most recent scan showed progression (new/worsening cancer)
- Your cancer has measurable disease that can be measured on scans or exams
- You are at least 18 years old, and your overall daily functioning is good (ECOG 0–1)
- Your blood counts and liver function are within required limits (enough white cells, platelets, hemoglobin, and acceptable AST/ALT)
- You can take pills by mouth (no feeding tube) and can follow study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
This Phase 2 trial tests whether bevacizumab plus oxaliplatin and TAS-102 works better and is safe as the first treatment for advanced colorectal (colon/rectum) cancer. You may be asked to meet specific health and blood-test requirements and avoid other cancer treatments during the study.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
This trial tests a combination of two drugs, TAS-102 (an oral chemotherapy) and bevacizumab (a targeted therapy), as a first treatment for advanced colorectal cancer that has spread. It may be an option for people who cannot have or do not tolerate standard combination chemotherapy.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.